MARKET

EDIT

EDIT

Editas Medicine
NASDAQ

Real-time Quotes | Nasdaq Last Sale

38.53
+1.11
+2.97%
Closed 17:12 06/14 EDT
OPEN
37.83
PREV CLOSE
37.42
HIGH
38.88
LOW
37.33
VOLUME
1.15M
TURNOVER
--
52 WEEK HIGH
99.95
52 WEEK LOW
26.50
MARKET CAP
2.62B
P/E (TTM)
-17.8058
1D
5D
1M
3M
1Y
5Y
CRISPR (CRSP) Up on Positive New Gene Therapy CTX001 Data
Zacks.com · 19h ago
BRIEF-Editas Medicine Strengthens Executive Leadership Team To Advance Pipeline And Support Long-Term Growth
reuters.com · 21h ago
Editas Medicine Presents Preclinical Data Supporting the Initiation of the EDIT-301 Phase 1/2 RUBY Clinical Trial for the Treatment of Sickle Cell Disease at the European Hematology Association Congress
Preclinical data demonstrated robust fetal hemoglobin (HbF) induction in erythroid progeny cells with no detection of off-target editing; cells showed reduced sickling and improved rheological behavior
GlobeNewswire · 4d ago
Editas Medicine Stock Is Believed To Be Possible Value Trap
GuruFocus News · 5d ago
Why Is Editas (EDIT) Down 2.9% Since Last Earnings Report?
Zacks.com · 06/04 15:31
Baird Starts Editas Medicine at Outperform with $44 Price Target
MT Newswires · 06/04 10:58
Here's Why We're Not Too Worried About Editas Medicine's (NASDAQ:EDIT) Cash Burn Situation
Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Simply Wall St. · 06/03 07:14
BRIEF-Editas Medicine Says Entered Into A Common Stock Sales Agreement Of Up To $300 Mln
reuters.com · 05/14 22:42
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of EDIT. Analyze the recent business situations of Editas Medicine through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 15 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average EDIT stock price target is 44.64 with a high estimate of 81.00 and a low estimate of 20.00.
EPS
Institutional Holdings
Institutions: 413
Institutional Holdings: 59.28M
% Owned: 87.25%
Shares Outstanding: 67.93M
TypeInstitutionsShares
Increased
112
5.07M
New
65
2.36M
Decreased
67
5.75M
Sold Out
59
1.41M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.10%
Pharmaceuticals & Medical Research
+0.13%
Key Executives
Chairman/President/Chief Executive Officer/Director
James Mullen
Chief Financial Officer
Michelle Robertson
Executive Vice President/Chief Scientific Officer
Mark Shearman
Senior Vice President
Harry Gill
Executive Vice President
Lisa Michaels
Lead Director/Independent Director
Jessica Hopfield
Other
Gad Berdugo
Independent Director
Meeta Chatterjee
Independent Director
Andrew Hirsch
Independent Director
David Scadden
Independent Director
Akshay Vaishnaw
No Data
  • All
  • Financials
  • Insiders
More
About EDIT
Editas Medicine, Inc. is a genome editing company. It is engaged in treating patients with genetically defined diseases by correcting their disease-causing genes. It operates through developing and commercializing genome editing technology segment. It is developing a genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR) technology. CRISPR uses a protein-ribonucleic acid (RNA) complex composed of an enzyme, including either CRISPR associated protein 9 (Cas9) or CRISPR from Prevotella and Francisella 1 (Cpf1), bound to a guide RNA molecule designed to recognize a particular deoxyribonucleic acid (DNA) sequence. Its platform consists of four components: nuclease engineering, delivery, control and specificity, and directed editing. Its programs include Eye Diseases, Engineered T Cell Therapies for Immuno-Oncology and additional research programs. It is developing a genome editing therapeutic for Leber Congenital Amaurosis type 10 (LCA10).

Webull offers kinds of Editas Medicine Inc stock information, including NASDAQ:EDIT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, EDIT stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading EDIT stock methods without spending real money on the virtual paper trading platform.